908 Devices (NASDAQ:MASS) Price Target Raised to $14.00

908 Devices (NASDAQ:MASS – Free Report) had its price objective boosted by Stifel Nicolaus from $12.00 to $14.00 in a research note issued to investors on Wednesday, MarketBeat Ratings reports. Stifel Nicolaus currently has a buy rating on the stock.

MASS has been the subject of a number of other reports. Roth Capital increased their price objective on 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Wall Street Zen downgraded 908 Devices from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, November 4th. Finally, Canaccord Genuity Group assumed coverage on 908 Devices in a research note on Thursday, September 10th. They issued a “buy” rating and a $13.50 price target for the company. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $13.67.

Get Our Latest Stock Analysis on 908 Devices

908 Devices Stock Performance

Shares of NASDAQ MASS opened at $9.74 on Wednesday. 908 Devices has a 52-week low of $5.03 and a 52-week high of $13.35. The firm has a 50 day moving average price of $11.17 and a two-hundred day moving average price of $8.56. The stock has a market cap of $404.99 million, a P/E ratio of -14.98 and a beta of 0.66.

908 Devices (NASDAQ:MASS – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The firm had revenue of $18.95 million during the quarter, compared to the consensus estimate of $18.31 million. 908 Devices had a negative net margin of 36.87% and a negative return on equity of 11.44%. Analysts predict that 908 Devices will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at 908 Devices

In other news, Director Christopher D. Brown sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $10.95, for a total value of $328,500.00. Following the transaction, the director owned 775,559 shares in the company, valued at approximately $8,492,371.05. The trade was a 3.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP John Kenneweg sold 21,399 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $10.11, for a total transaction of $216,343.89. Following the completion of the sale, the senior vice president directly owned 57,784 shares in the company, valued at approximately $584,196.24. This represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 134,115 shares of company stock worth $1,473,296. Company insiders own 28.20% of the company’s stock.

Institutional Trading of 908 Devices

A number of institutional investors have recently bought and sold shares of the company. Empowered Funds LLC bought a new position in shares of 908 Devices in the 3rd quarter worth about $613,000. 49 Wealth Management LLC acquired a new position in shares of 908 Devices in the 3rd quarter valued at about $169,000. Pier 88 Investment Partners LLC lifted its stake in shares of 908 Devices by 59.2% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 22,600 shares of the company’s stock valued at $279,000 after purchasing an additional 8,400 shares during the period. First Light Asset Management LLC boosted its position in shares of 908 Devices by 3.5% during the 2nd quarter. First Light Asset Management LLC now owns 6,282,804 shares of the company’s stock valued at $54,660,000 after purchasing an additional 210,241 shares in the last quarter. Finally, Gainline Financial Partners LLC bought a new stake in shares of 908 Devices during the 2nd quarter valued at about $107,000. Institutional investors own 88.06% of the company’s stock.

About 908 Devices

(Get Free Report)

908 Devices, Inc. develops analytical instruments that help users identify and measure chemicals and biomolecules. Its products use mass spectrometry and related technologies to bring laboratory-style analysis to settings where rapid results are needed. The company’s portfolio includes handheld devices for detecting and identifying chemical substances, as well as laboratory instruments and tools used in areas such as biopharmaceutical research and protein analysis. Its customers include organizations in public safety, defense, forensics, industrial markets and life sciences.

See Also

Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.